CBLLHealthcare · Medical DevicesThe 8 Wall Street analysts covering Ceribell, Inc. hold a median 12-month price target of $29 — +9.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 50 of 100 as at 31 Oct 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores Ceribell, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (97): The shares have been drifting up relative to others.
Issuance (25): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on CBLL, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +9.1% from it.
Of the 20 most recent actions, 3 moved their price target up and 1 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 2 Oct 2026 | TD Cowen | Maintains | Buy | $29 → $33 |
| 11 Sept 2026 | BTIG | Reiterates | Buy | — |
| 11 Sept 2026 | BTIG | Reiterates | Buy | $30 |
| 18 Aug 2026 | BTIG | Maintains | Buy | $28 → $30 |
| 18 Aug 2026 | BTIG | Maintains | Buy | — |
| 11 Aug 2026 | BTIG | Reiterates | Buy | — |
| 11 Aug 2026 | BTIG | Reiterates | Buy | $28 |
| 11 Aug 2026 | Canaccord Genuity | Maintains | Buy | — |
| 11 Aug 2026 | Canaccord Genuity | Maintains | Buy | $25 → $26 |
| 12 May 2026 | Canaccord Genuity | Maintains | Buy | — |
| 12 May 2026 | Canaccord Genuity | Maintains | Buy | $28 → $25 |
| 28 Jan 2026 | BTIG | Reiterates | Buy | — |
| 17 Dec 2025 | Canaccord Genuity | Maintains | Buy | — |
| 15 Dec 2025 | BTIG | Reiterates | Buy | — |
| 5 Nov 2025 | JP Morgan | Maintains | Overweight | — |
| 5 Nov 2025 | TD Cowen | Maintains | Buy | — |
| 21 Oct 2025 | Raymond James | Initiates | Strong Buy | — |
| 4 Apr 2025 | Ladenburg Thalmann | Initiates | Buy | — |
| 26 Feb 2025 | Canaccord Genuity | Maintains | Buy | — |
| 9 Dec 2024 | Canaccord Genuity | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
CBLL appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 30 Oct 2026, Ceribell, Inc. returned +134.8% against +12.4% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 96% of US stocks
Cheaper than 13% of US stocks
Cheaper than 11% of US stocks
Cheaper than 87% of US stocks
Higher than 79% of US stocks
Higher than 67% of US stocks
Higher than 97% of US stocks
Higher than 15% of US stocks
Higher than 8% of US stocks
Higher than 23% of US stocks
Higher than 17% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Ceribell, Inc. has a market value of $1.0B and an enterprise value of $912.7M.
Revenue in the twelve months to 30 June 2026: $102.0M. The latest quarter grew 32.5% year on year.
Net income over the same four quarters: −$66.0M, a −64.7% net margin.
Diluted earnings per share, trailing twelve months: $−1.76.
Free cash flow in the twelve months to 30 June 2026: −$54.7M.
Trailing P/E: −18.2×; forward P/E: −16.5× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Ceribell, Inc. employs 327 people — $312K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Ceribell, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Ceribell announced that CFO Scott Blumberg will participate in a fireside chat at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in New York City on November 11, 2026, at 7:00 a.m. PT / 10:00 a.m. ET.
Why it matters — CBLL watchers may note the scheduled investor-forum appearance by the company's CFO.
Ceribell said it will report third-quarter 2026 financial results after the close of trading on November 3, 2026. Management will discuss the results on a conference call at 1:30 p.m. PT / 4:30 p.m. ET that day.
Why it matters — CBLL watchers can note the scheduled date and time for the company's third-quarter results and management discussion.
Ceribell announced that the U.S. FDA cleared new software for the Ceribell System featuring quantitative EEG trending and amplitude-integrated EEG analysis. The company said the software makes it faster and easier for clinicians to interpret longitudinal brain activity and make clinical decisions.
Why it matters — A new FDA clearance for Ceribell's EEG analysis software strengthens the company's product offering and could help clinicians more quickly interpret brain-monitoring data.
CeriBell outlined plans to expand its brainwave-monitoring platform beyond seizure detection, introducing new products for delirium and pediatric patients, with stroke as a future target, while continuing to build its hospital customer base.
Why it matters — A CBLL watcher would care because the company's expansion into additional clinical indications signals a broader product pipeline and continued growth in its hospital customer base.
CeriBell, Inc. held its Q2 2026 earnings call, and the full conference call transcript has been published on Seeking Alpha. The transcript covers the company's quarterly earnings discussion for the period.
Why it matters — A CBLL watcher would care because the earnings call transcript provides insight into the company's quarterly financial results and management commentary.
The 8 Wall Street analysts covering Ceribell, Inc. have a median 12-month price target of $29, with estimates ranging from $24 to $33. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 8 analysts covering Ceribell, Inc., 8 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Ceribell, Inc. 50 out of 100 across roughly 4,600 US stocks as at 31 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 31 Oct 2026, Ceribell, Inc. ranks 50 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (97 of 100).
No one can know that. What the data says: the median 12-month target from 8 analysts implies +9.1% from the last close, and Ticker Nerd's factor model ranks Ceribell, Inc. 50 out of 100 as at 31 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Ceribell, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CBLL are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $24 to $33 over the next 12 months.
Ceribell, Inc. returned +134.8% over the 12 months to 30 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Ceribell Inc. is a medical technology company focused on acute-care neurodiagnostics.
The most recent item we track (GlobeNewsWire, 28 Oct 2026): "Ceribell to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum". Ceribell announced that CFO Scott Blumberg will participate in a fireside chat at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in New York City on November 11, 2026, at 7:00 a.m. PT / 10:00 a.m. ET.
Ceribell Inc. is a medical technology company focused on acute-care neurodiagnostics. Ceribell develops the Ceribell System, a point-of-care EEG platform designed to help clinicians detect and manage serious neurological conditions at the bedside. Its product suite includes disposable EEG headbands, a portable battery-operated recorder, cloud-based EEG software, and Clarity, an AI-powered seizure detection algorithm. These tools are used in hospitals and other urgent-care settings to support rapid brain monitoring, real-time interpretation, and faster clinical decision-making. Ceribell’s technology is aimed at making EEG more accessible, efficient, and practical for frontline healthcare teams working with suspected seizures and other critical neurological events.
CEO Dr. Xingjuan Chao Ph.D. · 327 employees · United States · https://www.ceribell.com
